Journal
CYTOKINE & GROWTH FACTOR REVIEWS
Volume 24, Issue 1, Pages 51-57Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2012.07.002
Keywords
IL-22; Th17; Th22; Autoimmune; Therapeutic
Categories
Funding
- National Natural Science Foundation of China [81102192, 30830089]
- Specialized Research Fund for the Doctoral Program of Higher Education of China [20113420120008]
- Grants for Scientific Research of BSKY from Anhui Medical University [XJ201014]
- National Institute of Health [AR059103, AI084359]
- ACR
- Arthritis Foundation
- Wright Foundation
Ask authors/readers for more resources
Interleukin-22 (IL-22) is an IL-10 family cytokine member that was recently discovered to be mainly produced by Th17 cells. Previous studies have indicated the importance of IL-22 in host defense against Gram-negative bacterial organisms (in gut and lung). Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of several autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), Sjogren's syndrome (SS) and psoriasis. Therapeutics targeting IL-22 therefore may have promise for treating various autoimmune diseases. In this review, we discuss the recent progression of the involvement of IL-22 in the development and pathogenesis of autoimmune diseases, as well as its clinical implications and therapeutic potential. (C) 2012 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available